Abstract:Heart failure (HF) with preserved ejection fraction (HFpEF) is the most common cause of pulmonary hypertension (PH) worldwide and is strongly associated with adverse clinical outcomes. The American Heart Association recently highlighted a call to action regarding the distinct lack of evidence-based treatments for PH due to poorly understood pathophysiology of PH attributable to HFpEF (PH-HFpEF). Prior studies have described cardiophysiological mechanisms to explain the development of isolated postcapillary PH (ipc-PH); however, the consequent increase in pulmonary vascular (PV) resistance (PVR) may lead to the less understood and more fatal combined pre- and postcapillary PH (cpc-PH). Metabolic disease and inflammatory dysregulation have been suggested to predispose PH, yet the molecular mechanisms are unknown. Although PH-HFpEF has been studied to partly share vasoactive neurohormonal mediators with primary pulmonary arterial hypertension (PAH), clinical trials that have targeted these pathways have been unsuccessful. The increased mortality of patients with PH-HFpEF necessitates further study into viable mechanistic targets involved in disease progression. We aim to summarize the current pathophysiological and clinical understanding of PH-HFpEF, highlight the role of known molecular mechanisms in the progression of PV disease, and introduce a novel concept that lipid metabolism may be attenuating and propagating PH-HFpEF.NEW & NOTEWORTHY Our review addresses pulmonary hypertension (PH) attributable to heart failure (HF) with preserved ejection fraction (HFpEF; PH-HFpEF). Current knowledge gaps in PH-HFpEF pathophysiology have led to a lack of therapeutic targets. Thus, we address identified knowledge gaps in a comprehensive review, focusing on current clinical epidemiology, known pathophysiology, and previously studied molecular mechanisms. We also introduce a comprehensive review of polyunsaturated fatty acid (PUFA) lipid inflammatory mediators in PH-HFpEF.

Insights into the relationship between serum uric acid and pulmonary hypertension (Review)

Epigenetic Modulation in the Initiation and Progression of Pulmonary Hypertension.

Epigenetic Regulation of Pulmonary Arterial Hypertension

Serum and pulmonary uric acid in pulmonary arterial hypertension

Pulmonary hypertension and metabolic disorders

Uric acid contributes to the progression of pulmonary hypertension in rodents and humans

The Prognostic Impact of Serum Uric Acid on Disease Severity and 5-Year Mortality in Patients With Idiopathic Pulmonary Artery Hypertension

Association of hyperuricemia and pulmonary hypertension: A systematic review and meta-analysis

Evaluating the role of serum uric acid in the risk stratification and therapeutic response of patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD)

Clinical features of chronic obstructive pulmonary disease with pulmonary hypertension

Utility of serum uric acid levels in excluding pulmonary hypertension in severe chronic lung disease: insights from a tertiary care center

Hyperuricemia in severe pulmonary hypertension

U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia

Unveiling the metabolic landscape of pulmonary hypertension: insights from metabolomics

Hyperuricemia and its related diseases: mechanisms and advances in therapy

Hyperuricemia as a prognostic factor in pulmonary arterial hypertension.

Uric acid and cardiovascular diseases: a reappraisal

Advances in the research of sulfur dioxide and pulmonary hypertension

Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations

Hyperuricemia in patients with pulmonary hypertension: A study in a tertiary care center

Novel insights into the pathobiology of pulmonary hypertension in heart failure with preserved ejection fraction